Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Med Suisse. 2012 Jan 11;8(323):11-3.

[Allergo-immunology. Clinical immunology].

[Article in French]

Author information

  • 1Service d'immunologie clinique et allergologie, HUG, 1211 Genève 14. carlo.chizzolini@unige.ch

Abstract

The past year has been characterized by significant novelties from the point of view of the clinical immunologist. With the BLISS 52 study showing that belimumab has the ability to decrease the activity of systemic lupus erythematosus (SLE) resistant to conventional therapy an important step towards the control of this difficult disease has been carried forward. In addition, the long-term results of the ALMS study have demonstrated that mycophenolate mofetil is superior to azathioprine in maintaining the remission in patients with severe lupus nephritis. Furthermore, the results of the RAVE and RITUXVASC studies have documented that rituximab is a valid alternative to cyclophosphamide in the control of ANCA associated vasculitis.

PMID:
22303732
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center